Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many efficacy/mechanism and hyperkalemia/monitoring statements align with the provided label sections, but several claims are unsupported by the supplied prescribing information (e.g., hypotension/fatigue as common side effects, dosing titration to 20 mg, ESRD not studied/not recommended, FDA/EMA approval dates, and generic availability). Multiple indication subcomponents (renal death/heart attack) are not explicitly worded exactly as in the label in the provided excerpts.
Category Scores
Accurate Statements
Kerendia is available as a 10 mg tablet formulation.
Supported by 3 DOSAGE FORMS AND STRENGTHS (10 mg strength listed).
The active ingredient in Kerendia is finerenone.
Supported by 11 DESCRIPTION (Kerendia contains finerenone; tablets contain 10 mg/20 mg/40 mg of finerenone).
Finerenone is a non-steroidal mineralocorticoid receptor antagonist.
Supported by 11 DESCRIPTION.
Finerenone works by blocking harmful effects of excess mineralocorticoid receptor activation that can contribute to kidney and heart damage in individuals with type 2 diabetes and CKD.
Supported by 12.1 Mechanism of Action (MR blockade; fibrosis/inflammation; MR mediated effects in kidney and non-epithelial tissues such as heart/blood vessels).
Common side effects of Kerendia include hyperkalemia (high potassium levels).
Supported by 5.1 Hyperkalemia and referenced discussion in 6 ADVERSE REACTIONS.
Patients are advised to monitor their potassium levels regularly, especially when starting or adjusting treatment with Kerendia.
Supported by 5.1 Hyperkalemia (measure serum potassium before initiation and measure periodically; more frequent monitoring for at-risk patients).
Kerendia is contraindicated in patients with concomitant use of strong CYP3A4 inhibitors.
Supported by 4 CONTRAINDICATIONS.
Kerendia can cause hyperkalemia.
Supported by 5.1 Hyperkalemia.
Caution is advised with Kerendia in patients with a history of, or risk factors for, hyperkalemia, including those taking other medications that can increase potassium levels.
Supported by 5.1 Hyperkalemia (risk increases with decreasing kidney function; more frequent monitoring may be necessary for patients at risk including those on concomitant medications that impair potassium excretion or increase serum potassium).
Kerendia is used to reduce the risk of kidney failure in adults with CKD associated with type 2 diabetes.
Supported by 1 INDICATIONS AND USAGE (end-stage kidney disease listed) and 14 CLINICAL STUDIES (kidney failure definition included in primary composite).
Kerendia is used to reduce the risk of cardiovascular death in adults with CKD associated with type 2 diabetes.
Supported by 1 INDICATIONS AND USAGE and 14 CLINICAL STUDIES (CV death component described in endpoints).
Kerendia is used to reduce the risk of non-fatal heart attack in adults with CKD associated with type 2 diabetes.
Supported as aligned with MI component of endpoints in 1 INDICATIONS AND USAGE and 14 CLINICAL STUDIES (non-fatal MI included).
Kerendia is used to reduce the risk of hospitalization for heart failure in adults with CKD associated with type 2 diabetes.
Supported by 1 INDICATIONS AND USAGE and 14 CLINICAL STUDIES (hospitalization for heart failure included).
Unsupported Statements
Common side effects of Kerendia include hypotension (low blood pressure).
Provided label excerpts do not list hypotension as an adverse reaction/side effect.
Common side effects of Kerendia can include fatigue.
Provided label excerpts do not list fatigue as an adverse reaction/side effect.
Kerendia doses can be increased to 20 mg once daily based on tolerability and potassium levels.
The provided label excerpts include only the recommended starting dose table and do not provide titration/increase guidance to 20 mg based on tolerability/potassium.
Use of Kerendia in patients with end-stage renal disease (ESRD) has not been studied and is not recommended.
Provided label excerpts do not contain a statement about ESRD being not studied/not recommended.
As of Kerendia's approval in 2021, there were no generic versions of Kerendia available.
Provided label excerpts do not address generic availability.
Kerendia received approval from the U.S. Food and Drug Administration (FDA) in July 2021.
Provided label excerpts do not include FDA approval date information.
Kerendia was approved by the European Medicines Agency (EMA) in February 2022.
Provided label excerpts do not include EMA approval date information.
Contradictions
Low
AI Statement
Kerendia can cause hyperkalemia.
Label Reference
N/A (no direct contradiction in provided excerpts; hyperkalemia is supported).
Important Omissions
Dose initiation is conditional on eGFR (10 mg for eGFR ≥25 to <60; 20 mg for eGFR ≥60; initiation not recommended for eGFR <25), but the extracted claims state a single 'typical' initiation of 10 mg once daily without the conditional eGFR basis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or imprecise dosing/population statements (e.g., titration to 20 mg, ESRD not studied/not recommended) and unsupported adverse-effect claims (hypotension/fatigue) could mislead risk assessment. Hyperkalemia risk/monitoring claims are aligned with the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several extracted claims are not supported by the supplied label sections (notably hypotension/fatigue as common side effects, ESRD not studied/not recommended, dosing increase guidance to 20 mg, approval dates, and generic availability).
Suggested Improvement
Limit claims strictly to wording supported by the provided label excerpts; replace 'typically initiated at 10 mg' with the label’s eGFR-based initiation table; remove unsupported adverse-effect and regulatory/timeline/generic-availability assertions; and only state 'not studied/not recommended' for populations when explicitly described in the provided label.